Orbactiv

Active Ingredient(s): Oritavancin Diphosphate
FDA Approved: * August 6, 2014
Pharm Company: * MEDICINES CO
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Orbactiv Overview

Oritavancin (INN, also known as LY333328, Orbactiv) is a novel semisynthetic glycopeptide antibiotic for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin.[1] In August 2014, the United States FDA approved oritavancin for treatment of skin infections.[2] Contents 1 In vitro activity 1.1 Mechanism 2 Clinical trials 3 History 4 References 5 External links In vitro activ...

Read more Orbactiv Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Oritavancin

Recent Orbactiv Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Orbactiv: (2 results)

Sorted by National Drug Code

• 65293-015 Orbactiv 400 mg Intravenous Injection, Powder, Lyophilized, for Solution by The Medicines Company
• 70842-140 Orbactiv 400 mg Intravenous Injection, Powder, Lyophilized, for Solution by Melinta Therapeutics, Inc.

Other drugs which contain Oritavancin Diphosphate or a similar ingredient: (1 result)

• ORITAVANCIN